Eupraxia Pharmaceuticals Inc. Common Stock EPRX
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $18.00 (+114.3% upside)
Key Stats
- Today's Range
- $7.39 – $8.40
- 50-Day Range
- $5.72 – $8.40
- 52-Week Range
- $5.04 – $9.32
- Volume
- 3.52 million shs
- Average Volume
- 484K shs
- Market Cap
- $555.02 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
Related Stocks
Compare head-to-head: EPRX vs NVDA·EPRX vs AAPL·EPRX vs GOOGL·EPRX vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.